Alpha 2.0
Login Register
» Articles » PMID: 28661738

Nonmaleficence, Nondisclosure, and Nocebo: Response to Open Peer Commentaries

Overview
Journal Am J Bioeth
Specialty Medical Ethics
Date 2017 Jun 30
PMID 28661738
Citations 2
Authors
John T Fortunato
Jason Adam Wasserman
Daniel Londyn Menkes
Affiliations
Soon will be listed here.
Citing Articles

One-year results after transitioning from etanercept originator to biosimilar in a setting promoting shared decision-making in rheumatology.

Muskens W, Rongen-van Dartel S, Teerenstra S, Adang E, van Riel P Rheumatol Adv Pract. 2020; 4(2):rkaa042.

PMID: 33005860 PMC: 7519774. DOI: 10.1093/rap/rkaa042.

The Biosimilar Nocebo Effect? A Systematic Review of Double-Blinded Versus Open-Label Studies.

Odinet J, Day C, Cruz J, Heindel G J Manag Care Spec Pharm. 2018; 24(10):952-959.

PMID: 30247100 PMC: 10398229. DOI: 10.18553/jmcp.2018.24.10.952.